UK Markets close in 7 hrs 38 mins
  • FTSE 100

    7,035.73
    +17.13 (+0.24%)
     
  • FTSE 250

    17,927.66
    -45.03 (-0.25%)
     
  • AIM

    832.14
    -1.45 (-0.17%)
     
  • GBP/EUR

    1.1042
    -0.0147 (-1.32%)
     
  • GBP/USD

    1.0689
    -0.0168 (-1.5477%)
     
  • BTC-GBP

    17,651.56
    -242.44 (-1.35%)
     
  • CMC Crypto 200

    432.97
    -11.57 (-2.60%)
     
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • DOW

    29,590.41
    -486.29 (-1.62%)
     
  • CRUDE OIL

    78.64
    -0.10 (-0.13%)
     
  • GOLD FUTURES

    1,653.70
    -1.90 (-0.11%)
     
  • NIKKEI 225

    26,431.55
    -722.28 (-2.66%)
     
  • HANG SENG

    17,892.78
    -40.49 (-0.23%)
     
  • DAX

    12,338.62
    +54.43 (+0.44%)
     
  • CAC 40

    5,822.96
    +39.55 (+0.68%)
     

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

·2-min read
LAVA Therapeutics N.V.
LAVA Therapeutics N.V.

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held virtually and in New York City.

Presentation Details
Format: Virtual Corporate Presentation
Date: Monday, September 12, 2022
Time: Available for on-demand viewing at 7:00 a.m. EDT

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com